Personal information

Other IDs

SciProfiles: 1603900
Loop profile: 2148387

Activities

Collapse all

Employment (3)

University of Central Lancashire: Preston, GB

Employment
Source: check_circle
University of Central Lancashire

University of Central Lancashire: Preston, GB

2022-01-03 to present | Senior Lecturer - Physician Associate Programme (School of Medicine)
Employment
Source: Self-asserted source
Emyr Bakker

University of Central Lancashire School of Medicine: Preston, Lancashire, GB

2017-12-01 to 2022-01-02 | Lecturer in Medical Sciences
Employment
Source: Self-asserted source
Emyr Bakker

Education and qualifications (2)

University of Salford: Salford, GB

2013 to 2017 | PhD Biological Sciences (Cancer Research)
Education
Source: Self-asserted source
Emyr Bakker

The University of Manchester: Manchester, GB

2009 to 2012 | BSc (Hons) Genetics
Education
Source: Self-asserted source
Emyr Bakker

Works (17)

Intratumor microbiota as a novel potential prognostic indicator in mesothelioma

Frontiers in Immunology
2023-03-14 | Journal article
DOI: 10.3389/fimmu.2023.1129513
Part of ISSN: 1664-3224
Contributors: Francesca Pentimalli; Marija Krstic-Demonacos; Caterina Costa; Luciano Mutti; Emyr Yosef Bakker
Source: Self-asserted source
Emyr Bakker

Patient-Level Omics Data Analysis Identifies Gene-Specific Survival Associations for a PD-1/PD-L1 Network in Pleural Mesothelioma

BioMedInformatics
2022-11 | Journal article | Author
DOI: 10.3390/biomedinformatics2040037
Contributors: Geraldine O'Connor; Emyr Bakker
Source: check_circle
Multidisciplinary Digital Publishing Institute

Molecular Mechanisms of PD-1 and PD-L1 Activity on a Pan-Cancer Basis: A Bioinformatic Exploratory Study

International Journal of Molecular Sciences
2021-05-22 | Journal article
DOI: 10.3390/ijms22115478
Part of ISSN: 1422-0067
Source: Self-asserted source
Emyr Bakker
grade
Preferred source (of 2)‎

The use of multi-omics data and approaches in breast cancer immunotherapy: a review.

Future oncology (London, England)
2020-08-28 | Journal article
DOI: 10.2217/fon-2020-0143
PMID: 32857605
Source: Self-asserted source
Emyr Bakker

The Treatment of Malignant Pleural Mesothelioma: From the Current Standard to Novel Possible Therapeutic Strategies

Malignant Pleural Mesothelioma
2019 | Book chapter
DOI: 10.1016/b978-0-12-812724-7.00010-1
Part of ISBN: 9780128127247
Source: Self-asserted source
Emyr Bakker

What can independent research for mesothelioma achieve to treat this orphan disease?

Expert opinion on investigational drugs
2019-07-01 | Journal article
DOI: 10.1080/13543784.2019.1638363
PMID: 31262194
Source: Self-asserted source
Emyr Bakker

Antitumor effects of a recombinant baculovirus displaying anti-HER2 scFv expressing Apoptin in HER2 positive SK-BR-3 breast cancer cells

Future Virology
2019-03 | Journal article
DOI: 10.2217/fvl-2018-0187
Part of ISSN: 1746-0794
Part of ISSN: 1746-0808
Source: Self-asserted source
Emyr Bakker

<i>BAP1</i> Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment

International Journal of Molecular Sciences
2019-01 | Journal article | Author
DOI: 10.3390/ijms20020429
Contributors: Alice Guazzelli; Parisa Meysami; Emyr Bakker; Constantinos Demonacos; Antonio Giordano; Marija Krstic-Demonacos; Luciano Mutti
Source: check_circle
Multidisciplinary Digital Publishing Institute

p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.

Journal of translational medicine
2018-10-13 | Journal article
DOI: 10.1186/s12967-018-1650-0
PMID: 30316293
PMC: PMC6186085
Source: Self-asserted source
Emyr Bakker

Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia.

PloS one
2017 | Journal article
DOI: 10.1371/journal.pone.0178606
PMID: 28582465
PMC: PMC5459454
Source: Self-asserted source
Emyr Bakker via Europe PubMed Central

Insight into glucocorticoid receptor signalling through interactome model analysis.

PLoS computational biology
2017-11 | Journal article
DOI: 10.1371/journal.pcbi.1005825
PMID: 29107989
PMC: PMC5690696
Source: Self-asserted source
Emyr Bakker via Europe PubMed Central

Immunotherapy advances for mesothelioma treatment.

Expert review of anticancer therapy
2017-09 | Journal article
DOI: 10.1080/14737140.2017.1358091
PMID: 28724330
Source: Self-asserted source
Emyr Bakker via Europe PubMed Central

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.

Expert opinion on investigational drugs
2017-08 | Journal article
DOI: 10.1080/13543784.2017.1351545
PMID: 28679291
Source: Self-asserted source
Emyr Bakker via Europe PubMed Central

Current and prospective pharmacotherapies for the treatment of pleural mesothelioma

Expert Opinion on Orphan Drugs
2017-06-03 | Journal article
DOI: 10.1080/21678707.2017.1325358
Part of ISSN: 2167-8707
Source: Self-asserted source
Emyr Bakker
grade
Preferred source (of 2)‎

Anti-CTLA-4 therapy for malignant mesothelioma.

Immunotherapy
2017-03 | Journal article
DOI: 10.2217/imt-2016-0123
PMID: 28231719
Source: Self-asserted source
Emyr Bakker via Europe PubMed Central

The role of microenvironment and immunity in drug response in leukemia.

Biochimica et biophysica acta
2016-03 | Journal article
DOI: 10.1016/j.bbamcr.2015.08.003
PMID: 26255027
Source: Self-asserted source
Emyr Bakker via Europe PubMed Central

Glucocorticoid receptor interactome

Endocrine Abstracts
2014-03-01 | Journal article
DOI: 10.1530/endoabs.34.p358
Part of ISSN: 1479-6848
Contributors: Emyr Bakker; Kun Tian; James Andrews; Constantinos Demonacos; Jean-Marc Schwartz; Marija Krstic-Demonacos
Source: Self-asserted source
Emyr Bakker via Crossref Metadata Search

Peer review (10 reviews for 3 publications/grants)

Review activity for Cells. (1)
Review activity for International journal of molecular sciences. (1)
Review activity for Journal of translational medicine. (8)
How many people are using ORCID?